Inhibition of growth stimulatory pathways has emerged as a major focus of targeted cancer drug development. New insights regarding potent, transient inhibition of cell signaling may challenge the dogma of medicinal chemistry and clinical trial design.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Kim Caesar
References
Evans, W.E. et al. N. Engl. J. Med. 314, 471–477 (1986).
Shah, N.P. et al. Cancer Cell 14, 485–493 (2008).
Druker, B.J. et al. N. Engl. J. Med. 344, 1031–1037 (2001).
Kantarjian, H. et al. Blood 103, 2873–2878 (2004).
Kantarjian, H. et al. Blood 109, 5143–5150 (2007).
Shah, N.P. et al. J. Clin. Oncol. 26, 3204–3212 (2008).
Karaman, M.W. et al. Nat. Biotechnol. 26, 127–132 (2008).
Wong, S. et al. Proc. Natl. Acad. Sci. USA 101, 17456–17461 (2004).
Luo, F.R. et al. Clin. Cancer Res. 12, 7180–7186 (2006).
Weinstein, I.B. Science 297, 63–64 (2002).
Janes, K.A., Reinhardt, H.C. & Yaffe, M.B. Cell 135, 343–354 (2008).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Bradner, J. A pulse at the heart of targeted therapy. Nat Chem Biol 5, 144–145 (2009). https://doi.org/10.1038/nchembio0309-144
Issue Date:
DOI: https://doi.org/10.1038/nchembio0309-144
